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Abstract 
 
 
Angiogenese bezeichnet die Entstehung von neuen Blutgefässen aus dem bereits 
bestehenden Netzwerk und stellt somit einen Schlüsselmechanismus für Entwicklung und 
Wachstum dar. Ephrine und ihre dazugehörigen Eph-Rezeptoren stellen eine der vier 
Familien von „Guidance-Molekülen“ für Axone dar, die auch eine sehr wichtige Rolle in 
der vaskulären Entwicklung und der Differenzierung zwischen Arterien und Venen 
spielen. Sie bilden die grösste Familie von Rezeptor-Tyrosin-Kinasen und verursachen 
durch komplexe Interaktion mit anderen Signalmolekülen und Signaltransduktionswegen 
eine biologische Antwort mit zwei unterschiedlichen Folgen- Repulsion oder Attraktion 
von Zellen. Die Eph-Ephrin Signalgebung wurde bereits in verschiedensten Aspekten 
untersucht, unter anderem in neuronalen Zellen, und wurde als potentielle Anti-Tumor 
Therapie eingestuft.  
Das Ziel dieser Arbeit war es, die Reaktion von Endothelzellen auf EphrinA5-EphA7 
Signalgebung bezüglich Migration und Proliferation zu untersuchen. Nachdem frühere 
Untersuchungen gezeigt haben, dass EphrinA5-EphA7 Expression zu Repulsion von 
neuronalen Zellen führt, wurden ähnliche Antworten in Endothelzellen erwartet. 
Die Schwerpunkte der Experimente stellten das Generieren von Ephrin-Fc und 
monomerischen Ephrin Konstrukten und deren Einsatz in funktionellen Tests mit HUVEC 
(human umbilical venous endothelial cells) dar. Diese basierten auf dem Vorwissen, dass 
EphrinA7 ein Zielgen des Transkriptionsfaktors SOX18 ist. Durch transiente Transfektion 
von HUVEC mit SOX18-IRES/GFP wurde die Expression von EphA7 ausgelöst.  
HUVEC, die mit SOX18/GFP transient transfektiert wurden, reagierten mit Retraktion auf 
die Konfrontation durch mit Antikörper geclustertem EphrinA5-Fc. Ein weiterer Ansatz, in 
dem Zellen mit SOX18/GFP Adenovirus infiziert und EphrinA5-Fc, das mit Protein G 
Polystyrene Kugeln geclustert wurde, ausgesetzt wurden, führte zu keiner Reaktion. In 
einem in vitro Wundheilungsversuch, in dem EphrinA5-Fc Fusionskonstrukte, EphrinA5 
Monomere und Kontroll-Fc verwendet wurden, wurden keine signifikanten Ergebnisse 
erzielt.  
Zusammenfassend kann man sagen, dass es sich bei den erzielten Daten um die ersten 
Schritte handelt, um die Rolle von EphA7 in Endothelzellen besser zu beleuchten, die in 
zukünftigen Studien weiterverfolgt werden sollten. 
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Abstract 
 
 
Angiogenesis denotes the generation of new blood vessels from the pre-existing network 
and is therefore a key mechanism in development and growth. Ephrins and their corre-
sponding Eph receptors form one of four families of axon guidance molecules, which have 
been revealed to be crucial players in vascular development and arteriovenous differentia-
ton. They constitute the largest family of receptor tyrosine kinases and evoke by complex 
interaction with other signalling molecules and signal transduction pathways a biological 
response with two different outcomes- repulsion or attraction of cells. Eph-ephrin signaling 
has already been extensively studied in various aspects, including neuronal cells, and has 
been considered as potential anti-tumor therapy. 
The purpose of this work was to investigate the response of endothelial cells to ephrinA5-
EphA7 signaling in the context of migration and proliferation. Since previous research has 
revealed that ephrinA5-EphA7 expression leads to repulsion of neuronal cells, similar res-
ponses were expected in endothelial cells. The experiments focused on the generation of 
ephrin_fc and monomeric ephrin constructs and theirs use in functional assays with HU-
VEC (human umbilical venous endothelial cells). They were based on previous findings 
that EphrinA7 is a target gene of the transcription factor SOX18. Expression of EphA7 was 
driven by transient transfection of HUVEC with SOX18-IRES/GFP. Confronting the cells 
with antibody-clustered ephrinA5-Fc lead to the expected retraction of the cells. 
Whereas HUVEC transiently transfected with SOX18/GFP showed retraction when treated 
with clustered ephrinA5-Fc, a complementary approach using adenovirus SOX18/GFP 
infected cells and protein G polystyrene particle-clustered ephrinA5-Fc lacked a response. 
A wound healing assay, in which ephrinA5-Fc fusion constructs, ephrinA5 monomers and 
control Fc have been used, did not show any noticeable results. Therefore, the data ob-
tained so far are a first step towards the elucidation of the role of EphA7 in endothelial 
cells but need to be followed up in future studies. 
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1 Introduction  
 
 
1.1 The vascular system 
 
 
The vascular network of blood and lymphatic vessels in the body is built up by the endo-
thelium, which is a specialized form of the epithelium. Among the many functions of the 
endothelium are the control of blood pressure, blood clotting, trafficking of cells and nu-
trients, and inflammation. Vascular dysfunctions are involved in artherosclerosis, coagula-
tion disorders, oedema formation and malignant cell growth. Also chronic diseases like 
diabetes, arthritis, psoriasis and Crohn´s disease are traced back to impaired vessel func-
tion.  
Endothelial cells form a single layer that surrounds the lumen of the vessel. A basal lamina 
separates the endothelium from the outer layers of the vessel, which consist of smooth 
muscle cells, fibroblasts, pericytes, the basement membrane and the extracellular matrix. 
Capillaries are only loosely covered by pericytes, whereas larger vessels are supported by 
smooth muscle cells and multiple layers of extracellular matrix.  
The endothelium is a highly active organ which displays heterogeneity in various tissues 
and organs. The high endothelial venules of the lymph nodes, the fenestrated endothelium 
of the gastrointestinal tract and the kidney glomeruli, and the tight blood-brain barrier are 
just a few examples of variations of the endothelium. 
 
 
1.2 Angiogenesis 
 
 
After formation of endothelial cell precursors, the angioblasts, from the mesoderm in the 
developing embryo, they generate blood vessels de novo which build the early vascular 
plexus. This process is called vasculogenesis. Angiogenesis describes the generation of 
further blood vessels from the pre-existing network. Two different processes have been 
described: sprouting and non-sprouting angiogenesis or intussusception (Risau, 1997). In 
the process of sprouting angiogenesis, cells migrate and proliferate after the extracellular 
matrix is proteolytically degraded. The formation of a lumen is followed by the functional 
maturation of the endothelium. In the process of non-sprouting angiogenesis, which was 
first described in the embryonic lung, pre-existing vessels are split. When a wide lumen is 
formed by proliferation of endothelial cells inside a vessel, it can be split by transcapillary 
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pillars or fusion and splitting of capillaries. Vessels generated by vasculogenesis form typ-
ical tissues like the lung, pancreas, spleen, the heart tube and dorsal aorta. Tissues like the 
kidney and brain are established by angiogenesis.  
 
 
 
 
Figure 1. Vascular development. All these processes contain a multitude of key regulators. The 
existence of a bipotential precursor, the haemangioblast, has been suggested for a long time. Re-
modelling involves the recruitment of smooth muscle cells and pericytes to the vessels (Risau, 
1997). 
 
It was shown that both processes of vascularization, vasculogenesis and angiogenesis, 
share quite a number of regulatory mechanisms.  
Different receptor families are expressed on endothelial cells, which are activated by sig-
nals from the target tissues (Mosch et al., 2009). VEGF, Tie and ephrin receptors seem to 
play a dominant part in angiogenesis (Hofer et al., 2006). Endothelial cells also express 
receptors not specific for this cell type, such as acidic and basic fibroblast growth factor 
(aFGF, bFGF), platelet-derived growth factor (PDGF), and epidermal growth factor (EGF) 
receptors, which are all receptor tyrosine kinases. The transforming growth factor beta 
(TGF- ) receptor, which has serine/threonine kinase activity, plays a role in vessel matura-
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tion. Various other factors have been identified to be involved in vascularization, such as 
cell-adhesion molecules.  
Angiogenesis, which is a multi-step process, is triggered in special physiological condi-
tions, e.g. the ovarian cycle and wound healing, and in pathological conditions. Tumor 
growth and spreading is supported by the mechanisms of angiogenesis, thus making them 
an important target for therapies. 
 
 
Figure 2. Angiogenesis is a multi-step process. Once the endothelial cells (ECs) are activated, the 
extracellular matrix  is degraded. After proliferation and migration of the ECs, the extracellular 
matrix is remodeled followed by tube and loop formation. Vascular stabilization is the last step 
ensuring a save blood flow (The Angiogenesis Foundation. www.angio.org). 
  
 
1.2.1 VEGF and receptors 
 
VEGFs, which are dimeric glycoproteins, belong to the PDGF family of growth factors 
and can be divided into VEGF-A, -B, -C, -D and PIGF. Their importance has been shown 
in knock-out mice, which die in utero (Beck et al., 1997). VEGFs are key regulators of 
angiogenesis, leading to important functions like regulating blood vessel formation during 
embryonic development and in wound healing. Furthermore, they are important for vessel 
homeostasis in the adult. VEGF expression is strongly driven in hypoxic reagions, there-
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fore resulting in an induction of angiogenesis. Furthermore, it is also induced by various 
cytokines and growth factors, e.g. TGF  and , IL 1 and Il 6. VEGF receptors are trans-
membrane receptor tyrosine kinases with an extracellular domain containing seven immu-
noglobulin-like domains and a split tyrosine kinase domain in their intracellular part. There 
are three members of the VEGF receptor family: VEGFR-1 (Flt-1), VEGFR-2 (KDR in 
humans/ Flk-1 in mice) and VEGFR-3 (Flt-4) (Breier et al., 1996). 
 
 
 
Figure 3. VEGF receptors and their ligands. VEGFR-1 and VEGFR-2 bind VEGF-A, VEGFR-1 
binds VEGF-B and PIGF (placenta growth factor), VEGF-C and –D are ligands of VEGFR-3. Re-
lated proteins are VEGF-E, which is expressed by poxviruses of the Orf family, and VEGF-F, 
which was identified in snake venoms. Both ligands bind toVEGFR-2 (Cébe-Suarez et al., 2006). 
 
The several roles of different VEGFRs have also been elucidated in knock-out mice (Cébe-
Suarez et al., 2006). VEGFR-1 regulates blood vessel morphogenesis. Most is known 
about VEGF-A/VEGFR-2 signaling, which is able to induce more than 100 genes. 
VEGFR-2 is important in angiogenic signaling, regulation of vessel permeability and the 
organization of the cytoskeleton. Furthermore, it promotes mitogenesis and is essential for 
cell survival. The related VEGFR-3 is described as a regulator of lymphangiogenesis as it 
is expressed after development in the lymphatic endothelium. 
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1.2.2 Tie- Angiopoietin system 
 
Another class of receptor tyrosine kinases preferentially expressed in endothelial cells is 
formed by Tie1 and Tie2 (Tek) (Mustonen et al., 1995). Both receptors are necessary for 
differentiation of endothelial cells and establishment of vessel integrity. 
Angiopoietin 1-4 are the ligands for Tie2, whereas opinions differ concerning the ligands 
for Tie1. It was suggested that Ang1 and Ang4 can activate Tie1 and its interaction with 
Tie2. Tie receptors play a role in later stages of vascularization compared to VEGF signal-
ing. They are involved in remodeling and maturation of the vessels. 
 
1.3 Guidance of endothelial cells 
 
The vascular and nervous systems share quite a number of similarities. Both build a 
branching network and often display a similar pattern in tissues. Axons have to find their 
correct way and migrate in the right direction. A sensory structure at the tip of the axon, 
called growth cone, allows reaction to guidance cues and defines the direction of growth. 
Studies have shown that there are also specialized endothelial cells called tip cells, reacting 
to attractive and repulsive cues and therefore contributing to the navigation of blood ves-
sels. Four families of axon guidance molecules have been discovered to also regulate vas-
cular development (Carmeliet et al., 2005; Suchting et al., 2005). 
These families are the Netrins with their DCC and UNC5 receptors, Slits with their Robo 
receptors, Semaphorins with their Neuropilin (NRP) and Plexin receptors, and Ephrins 
with their Eph receptors. 
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Figure 4. Four families of receptors and ligands involved in axon guidance and blood vessel 
development. Additionally to semaphorins, also VEGF binds to neuropilins (Klagsbrun et al., 
2005). 
 
Through expression gradients of these signaling molecules, offering either attractive or 
repulsive signals to the tip cells, correct movement of vessels is ensured. 
To study endothelial guidance cells, the zebrafish has proven to be a useful model organ-
ism (Suchting et al., 2005). The correct patterning of intersomitic vessels (ISV) is ab-
olished in knockdown of the guidance molecules PlexinD1, UNC5B and Robo4.  
ISV have to follow both attractive cues to sprout from the dorsal aorta and grow dorsally in 
the intersomitic space, and repulsive cues not to invade the somites. Only when the com-
plex interplay of several signaling molecules works, correct guidance of the vessels can be 
ensured. 
One family of guidance cues is formed by Netrins, which are ligands for DCC and UNC5 
receptors. Netrins where shown to guide axons to the midline of the brain, offering them an 
attractive signal by binding to DCC receptors. The interaction with UNC5 receptors, which 
can form heterodimers with DCCs to mediate a long-range signal, results in axon repul-
sion. UNC5b, which is also expressed in mammalian endothelial cells along with 3 other 
UNC5 receptors, was revealed to regulate blood vessel guidance. 
Slits function as long- or short- range cues important for guidance of axons at the midline 
dependent of the expression level of their Roundabouts (Robo) receptors. Slits have been 
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identified to be necessary for repulsion of axons from the midline. Four Robos have been 
identified in vertrebrates, including Robo4, which shows a different structure than the other 
receptors from this family and seems to be highly expressed by endothelial cells. 
Semaphorins also provide guidance cues for axons and are important players in neural wir-
ing processes. Whereas membrane-bound Semaphorins bind to Plexins, secreted Semapho-
rins bind to Neuropilins, which are co-receptors for Plexin signaling. 
Studies have shown that Sema3A is not the only binding partner of Neuropilin-1 (NP1), 
but also binds to VEGF165. Both molecules compete for binding to the receptor, leading to 
different signal responses. Competition between Sema3F and VEGF165 was also demon-
strated in binding to NP2. These examples show again, how complex the network around 
the endothelial guidance molecules is and that lots of other different factors are involved. 
Experiments in mice and zebrafish have elucidated the crucial role of semaphorins and 
their receptors as regulators of vessel guidance and branching. 
 
1.4 Ephrins  
 
 
Eph receptors (erythropoietin-producing human hepatocellular carcinoma) and their li-
gands, the ephrins (Eph family receptor interacting proteins), which have originally been 
identified as neuronal pathfinding molecules and regulators of nervous system patterning 
(Frisén et al., 1997) and development of the vertebrate brain, were – like the other three 
families described above- shown to be important players in regulation of vascular assembly 
and differentiation in development and of vascular homeostasis in the adult (Augustin et 
al., 2003). In the last few years, the various roles of Eph-ephrin signaling have been eluci-
dated (Kullander et al., 2002). 
1.4.1 Structure and Function 
 
Ephrin receptors turned out to constitute the largest family of receptor tyrosine kinases 
(RTKs). The glycosylated extracellular domain of Eph receptors consists of an N-terminal 
ephrin binding domain, a cysteine rich domain and two fibronectin type III motifs. It is 
connected via a single transmembrane spanning domain with the intracellular part, contain-
ing a tyrosine kinase domain and a sterile alpha motif (SAM) and PDZ-binding motif, both 
for protein interactions. 
Ephs and their ligands are divided into A and B subfamilies, dependent on the structural 
features of the ligands (Figure 5). Ligands of the EphA receptors are plasma membrane 
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molecules with a glycosyl-phosphatidyl inositol (GPI) anchor. Ligands of the EphB recep-
tors were identified as transmembrane molecules, containing a short cytoplasmic reagion 
and a PDZ domain for protein interactions in their intracellular part. In the human genome, 
nine EphA receptors and corresponding 5 ephrinA ligands, and five EphB receptors to-
gether with 3 ephrinB ligands have been identified. Binding within the A or B subfamilies 
happens preferentially, but it was also shown that crosstalk can occur. EphA4 and EphB2 
are well-known exceptions, which also bind to ephrinB2 and ephrinA5 (Pasquale, 2010; 
Miao et al., 2009). Eph-ephrin signaling is dependent on cell-cell contact and is able to 
proceed bidirectionally. Forward signaling into the receptor expressing cell needs the Eph 
kinase activity, leading to autophosphorylation of intracellular tyrosine residues and further 
to activation of downstream signalling molecules. Reverse signaling into the ligand ex-
pressing cell is triggered by phosphorylation of tyrosine residues in the cytoplasmic rea-
gion of ephrinB ligands by Src (Sarcoma) kinases. Also ephrinA ligands are capable of 
reverse signalling, as it was proven in C. elegans. It was shown, that Eph receptors and 
ephrins are also able to signal independently from each other by interaction with other sig-
naling systems. 
 
 
Figure 5. The structure of Eph receptors and their ligands (Kullander et al, 2002). 
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Several experiments have demonstrated, that clustering of ephrins is crucial for activating 
the receptor, since soluble ephrins do not evoke signaling in the receptor (Davis et al., 
1994; Mellitzer et al., 2000).  
An active Eph-ephrin complex consists of at least two receptors and two ligands, which 
undergo dimerization. The degree of clustering of the ligands affects the degree of Eph-
ephrin clustering, resulting in a corresponding strength of biological effects (Frisén et al., 
1999).  Interactions via different protein binding domains in the structure of Ephs and eph-
rins may also lead to oligomerization of the complex (Poliakov et al., 2004). Interestingly, 
also non-activated receptors are being recruited to the complex and phosphorylated. The 
multimeric structure of the Eph-ephrin complexes allows phosphorylation of the involved 
molecules, stimulating further signaling cascades through other signal transduction path-
ways.  
 
1.4.2 Signaling pathways involved in Eph-ephrin signaling 
 
1.4.2.1 The role of adaptor and scaffolding proteins 
 
A large number of signaling molecules and complex signaling pathways are involved in 
linking Ephs and ephrins to the cellular responses (Figure 6). 
Several phosphotyrosines on the Eph receptors have been identified as binding sites for 
adaptor proteins like SH2 (Scr Homology 2) domain proteins that initiate signal transduc-
tion pathways (Mellitzer et al., 2000). Among these are the cytoplasmic tyrosine kinases 
Fyn, Src, Nck and Crk, RasGAP, LMW-PTP (low molecular weight phosphotyrosine 
phosphatase), PI3K (phosphatidyl-inositol-3 kinase) and other adaptor proteins like Grb2, 
Grb10 and SLAP (Src-like adaptor protein). It was shown, that LMW-PTP and Nck are 
capable of leading to cell attachment by interacting with integrins. Activated EphB4 recep-
tors were shown to interact with PI3K and as a result trigger endothelial cell migration and 
proliferation (Surawska et al., 2004). Eph receptor bound ephrinB ligands becomes phos-
phorylated by Src family kinases, which leads to the onset of further downstream signal-
ing.  The tyrosine kinase Abl (Abelson) and Arg (Abl-related gene) have also been identi-
fied as binding partners of EphB2 and EphA4 receptors. 
Since ephrinB ligands feature a cytoplasmic PDZ domain, a number of PDZ domain pro-
teins, such as GRIP1 (glutamate-receptor-containing protein 1), GRIP2 and PHIP (ephrin-
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interacting protein) is able to bind there. GRIP proteins were suggested to act as scaffold-
ing proteins for the signaling complex, since they are found together with Ephs and ephrins 
in membrane rafts, promoting interaction with downstream signaling pathways.  
Binding of proteins to Ephs and ephrins is not necessarily dependent on phosphorylation, 
as it was shown for GEFs (guanine exchange factors) for Rho family proteins and PDZ 
domain proteins. 
Eph-ephrin signaling is capable of triggering changes in the actin cytoskeleton when me-
diating repulsion or adhesion. It could be shown, that Eph receptors modulate the activity 
of integrins, which transduce signals between the extracellular matrix and the actin cy-
toskeleton.  
To add even more complexity, the extent of receptor clustering determines the cellular re-
sponse as the degree of the clustering affects which signaling proteins are being activated. 
Experiments with EphB2 receptor expressing cells have provided interesting results. In 
case of EphB2 overexpression, cell adhesion was inhibited. As SHEP1 (SH2 domain-
containing Eph receptor-binding protein 1) links EphB2 to R-Ras, a tyrosine residue of R-
Ras gets phosphorylated and therefore abolishes the binding to Raf-1. As a consequence, 
integrin-mediated adhesion is downregulated. It was demonstrated in various other expe-
riments, that low-degree clustering of Ephs and ephrins supports integrin-mediated adhe-
sion, whereas high-degree clustering causes de-adhesion. 
 
1.4.2.2 G proteins link Eph-ephrin signalling and the cytoskeleton 
 
Eph-ephrin signaling regulates a variety of different signaling pathways in a complex man-
ner. G proteins, like members of the Ras and Rho family of GTPases, constitute the biggest 
groups of affected signaling molecules (Poliakov et al., 2004). It is very important to eluci-
date the link between Eph-ephrin signaling and the Ras and Rho family members, because 
they play a huge role in regulation of the cytoskeleton, cell migration, proliferation and 
adhesion. They are activated by GEFs (guanine nucleotide exchange factors), which pro-
mote the exchange of GDP to GTP. Several studies have revealed, that a number of GEFs 
are either directly bound by Eph receptors or indirectly activated, as Ephs and ephrinB 
ligands induce PI3K signalling. GAPs (GTPase-activating proteins) reverse the action of 
GEFs and are also regulated by Eph-ephrin signaling. The three Rho family GTPases 
Cdc42, Rac1 and RhoA are key regulators of reorganization of the actin cytoskeleton.  
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Among the multitude of players in downstream signaling of Ephs and ephrins, RhoA was 
identified as an important member. When stimulating EphA3 expressing cells with ephri-
nA5, RhoA is activated and leads to deadhesion and rounding up of the cells by reorgani-
zation of the cytoskeleton. Lawrenson and her colleagues have made the discovery, that 
ephrinA5-EphA3 signalling modulates RhoA activity and therefore leads to reorganization 
of the cytoskeleton. It was shown in melanoma cell lines, that ephrinA5 causes rounding 
and detachment of EphA3 expressing cells. The adaptor protein CrkII is binding to tyro-
sine-phosphorylated EphA3 and as a result, transiently activates RhoA.    
 
It has been shown in neurons that ROCK (Rho kinase) is an important component down-
stream from RhoA (Noren et al., 2003) and therefore also plays a role in the cellular re-
sponse to ephrinA5. Furthermore, the guanine nucleotide exchange factors Ephexin (Eph-
interacting exchange protein) and Vms-RhoGEF could be identified as a link between 
EphA receptors and the activation of RhoA. Ephexin is not only expressed in the nervous 
system, but also in liver and kidney (Kullander et al., 2002). It was demonstated in vitro, 
that it activates RhoA, but inhibits Cdc42 and Rac1. 
EphB receptors activate Rac1 and Cdc42 by binding the exchange factors Intersectin and 
Kalirin. It was further suggested, that Dishevelled could be a link both between EphBs and 
RhoA, and ephrinB ligands and RhoA. 
Brantley-Sieders et al. (2003) have pointed out the important role of EphA2 in context of 
endothelial cell migration and assembly. Upon activation of the receptor with ephrinA1, 
Rac1 is activated, which was shown to be essential for EphA2 mediated cell responses. 
Further experiments have revealed that the p85 regulatory subunit of PI3K is associated 
with activated EphA2. Therefore, PI3K is a crucial link between EphA2 and Rac1. 
It is now well-known, that Eph receptors can either positively or negatively regulate Rho 
GTPase activity by interacting with GEFs or GAPs. 
 
1.4.2.3 Negative regulation of the MAPK pathway 
 
As mentioned above, Eph-ephrin signaling also regulates the activity of Ras family pro-
teins, which are key players in the MAPK (mitogen-activated protein kinase) pathway. In 
most cases, Eph receptors were shown to inhibit this pathway. The MAPK pathway causes 
cellular responses in the presence of growth factors, like PDGF, VEGF, EGF and angi-
opoietin1. Activation of Ras (mostly H-Ras), which happens when the Grb2 (growth factor 
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receptor bound protein 2)/Sos (Son of sevenless) complex is recruited, triggers a phospho-
rylation cascade, leading to cell proliferation and differentiation.   
Dail and her colleagues (2005) have elucidated the mechanisms of Eph-mediated regula-
tion of R-Ras. The active form of R-Ras is part of signaling pathways leading to cell adhe-
sion and migration. When it is negatively regulated, inhibition of these responses was ob-
served. Several experiments have lead to the conclusion, that both activated EphA and 
EphB receptors inactivate R-Ras using two different mechanisms. First, through GTP hy-
drolysis by binding of p120RasGAP, a GTPase-activating protein acting on Ras, rendering 
Ras inactive. Second, through phosphorylation of Ras in the effector domain. 
Another interesting approach by Parri et al. (2005) lead to the conclusion, that LMW-PTP 
(low molecular weight protein-tyrosine phosphastase) negatively regulates EphA2-
ephrinA1 mediated repulsive response in cells. LMW-PTP, which only associates with 
activated EphA2, regulates the phosphorylation level of the receptor and therefore its func-
tion. As it was already demonstrated before, binding of p120RasGAP to Eph receptors 
leads to a downregulation of the MAPK pathway. LMW-PTP inhibits binding of 
p120RasGTP and as a result, blocks inhibition of the MAPK pathway.  
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Figure 6. Overview over the interaction of an activated Eph-receptor with various adaptor proteins. 
(Kullander et al., 2002) 
 
Recently, it was shown that Ephs and ephrins are also capable of regulating heterotrimeric 
G proteins. Interestingly, ephrinB ligands can also be bound by PDGF (platelet derived 
growth factor) and FGF (fibroblast growth factor) receptors, showing that crosstalk be-
tween different signaling networks plays a role.  
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1.4.3 Repulsion versus adhesion 
 
As already described above, both the degree of clustering of Eph receptors and ephrin li-
gands and the level of Eph phosphorylation influence the sigalling outcome and the cellu-
lar response. The complex interactions between Eph signaling and a big number of other 
signaling pathways can result either in repulsion or adhesion. Various mechanisms have 
been discovered, how the balance between repulsion and adhesion is maintained (Halloran 
et al., 2006; Poliakov et al., 2004).  
One way to allow separation of cells is by either uni- or bidirectional transendocytosis of 
the EphB-ephrinB signaling complex. Activated EphB receptors trigger Ras-dependent 
cytoskeletal assembly, allowing endocytosis of the EphB-ephrinB complex (Wilkinson, 
2003). Is has not been elucidated yet, if Eph-ephrin signaling continues inside the cell. 
However, it seems possible, since the Ephs end ephrins are endocytosed as full-length pro-
teins. Blocking of endocytosis, which happens when receptor or ligand, or both are trun-
cated, results in adhesion of the cells. The question, if EphA-ephrinA complexes are also 
internalized, is still not solved. 
The proteolytic cleavage of extracellular domains of ephrins is another mechanism leading 
to detachment of cells. It is best described for ephrinA ligands. The metalloprotease 
ADAM10 (A disintegrin and metalloprotease 10)/kuzbanian associates in cis with EphA3 
and is not active, before ephrinA5 binds to its receptor. The cysteine-rich domain of 
ADAM10 recognizes EphA3-ephrinA5 complexes, which activates the enzyme function. 
Consequentially, ephrinA5 is cleaved in trans (Figure 7).  
 
 
Figure 7. The mechanism of ADAM10 metalloprotease-mediated ephrinA5 cleavage (Janes et al, 
2005) 
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In most cases, forward signaling results in a repulsive response, whereas reverse signaling 
leads to adhesion. Some mechanisms have been discovered, which shift the response to-
ward adhesion by blocking forward sigalling (Figure 8). 
When truncated versions of Eph receptors, possessing no kinase domain, are co-expressed 
with full-length Ephs, adhesion is favored. It was already suggested by Holmberg et al. 
(2000), that different splice forms of an Eph receptor determine either repulsion or adhe-
sion. In the absence of ephrinA5 and EphA7, neural folds in mice are not able to fuse at the 
dorsal midline. It could be shown, that three different splice variants of EphA7 receptor are 
expressed at the edges of neural folds- one full length (FL) receptor and 2 truncated (T1 
and T2) versions without kinase domain. Expression of EphA7-FL and ephrinA5 in endo-
thelial cells lead to repulsion between receptor and ligand expressing cells. When EphA7-
T1 was co-expressed, this response could not be observed. EphA7-T1 was shown to reduce 
ligand-induced tyrosine phosphorylation of EphA7-FL and as a result to trigger adhesion, 
not repulsion.  
Cis expression of ephrinA ligands to EphA receptors abolishes signaling of EphA, since 
ephrinA binds to one of its fibronectin III domains and as a result, prevents phosphoryla-
tion of the receptor. This mechanism can be abolished, if EphAs and ephrinAs are ex-
pressed in different membrane domains, not allowing their cis interaction. 
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Figure 8. Mechanisms in altering the signaling outcome. (Halloran et al., 2006) 
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1.4.4 Expression of Ephs and ephrins in different cell types 
  
Eph-ephrin signaling became highly interesting, since it was shown that it is crucial both in 
neuronal and vascular development. Ephs and ephrins are expressed in nearly all embryo-
nic tissues and in a huge variety of other cells in adult vertebrates, e.g. neuronal cells, en-
dothelial cells, smooth muscle cells, epithelial cells, circulating leukocytes, bone marrow 
cells and tumor cells (Miao et al., 2009; Poliakov et al., 2004). Here, just some of the many 
implications of this complex signaling system in biological systems, will be illustrated. 
 
1.4.4.1 Neuronal pathfinding molecules 
 
As described above, Eph receptors and ephrin ligands have been, together with three other 
families of signalling molecules, first described as crucial players in neuronal development 
and in the adult brain. One of the first experiments on the quest for identifying neuronal 
guidance molecules was leading to the conclusion, that axons were repelled by ephrinA5 as 
well as by ephrinA2 (Frisen et al., 1999). Zimmer and her colleagues (2008) have demon-
strated the importance of the repulsive effect of ephrinA5 on migrating cortical interneu-
rons expressing EphA4 to ensure a safe and correct pathway from the ganglionic eminis-
cences into the neocortex. 
A correct axonal pathway is critical for formation of topographic connections between the 
neuronal cell bodies and their targets in other tissues. Ephs and ephrins of the A family are 
required for anterior-posterior mapping, whereas EphB receptors and ephrinB ligands are 
important players in dorsal-ventral mapping. Ephs and ephrins show a graded expression in 
the nervous system, making offering of re-und propulsive cues possible. Lower expression 
leads to lower clustering of receptors and ligands, resulting in axon growth. High cluster-
ing leads to repulsive signaling. Studies with knock-out mice have shown that EphA8, 
EphB2 and EphB3 are essential for correct axonal crossing of the midline (Frisen et al., 
1999).  
Ephs and ephrins are involved into the topographic mapping of the retinotectal system as 
well (Mellitzer et al., 2000). Retinal axons show a graded expression of EphA3, whereas 
ephrinA2 and ephrinA5 are gradually expressed in the tectum, enabling regulation the 
growth and the direction of the axonal projections from the retina to the tectum. 
Eph-ephrin signalling can also increase cell adhesion, as shown by Sela-Donenfeld et al. 
(2005). They have demonstrated that Eph-ephrin signaling is able to sharpen boundaries in 
23 
 
the complex organisation of the hindbrain into rhombomeres. EphA4 mediates both repul-
sion to restrict intermingling of cells at interfaces and adhesion of cells within rhombo-
meres. 
As one of many other examples, ephrinA5 was shown to play a role in neural tube closure, 
which was quite surprising because its interaction with EphA7 was known to mediate re-
pulsion in in vitro experiments with axons. EphrinA5 is expressed at the edges of the dor-
sal neural folds together with the EphA7 receptor. In the absence of EphA7 and ephrinA5, 
neural tube fusion is impaired (Holmberg et al., 2000). 
 
1.4.4.2 Expression in endothelial cells 
 
Eph-ephrin signalling controls vascular development, vessel guidance and morphogenesis. 
EphB receptors and their ligands have been shown to be essential mediators in arterioven-
ous differentiation during embryonic angiogenesis (Augustin et al, 2003; Adams et al, 
2000). Two crucial players in establishing vascular borders are ephrinB2 and EphB4. Eph-
rinB2 is expressed by arterial endothelial cells, whereas EphB4 is a marker of venous en-
dothelial cells. Their pro- and repulsive activities establish the boundary between arteries 
and veins by preventing cell intermingling. EphrinB2-deficient mice die because of the 
inability to form a proper network of arterial and venous endothelial cells (Mellitzer et al., 
2000). The asymmetric expression of EphB4 and ephrinB2 was also shown in the adult, 
suggesting that their interaction also plays a role in controlling vascular homeostasis. In 
vitro, EphB4 receptors activated by ephrinB2 cause endothelial cell proliferation and mi-
gration (Mosch et al., 2009). Even more players in vascular patterning have been identified 
in different experiments, making the picture more complex. EphB3, EphB4 and ephrinB1 
are expressed by venous cells. Arterial endothelial cells express EphB3, EphB4, ephrinB1 
and ephrin B2. 
 
An important pair of the A-class of Ephs/ephrins involved in angiogenesis is EphA2 and 
ephrinA1. EphrinA1 was the first identified Eph receptor ligand and showed to be induced 
by VEGF. Tang et al. (2005) did not only demonstrate, that ephrinA1 enhanced vascular 
endothelial migration and induced tube formation, but also that green tea catechin epigal-
locatechin gallate (EGCG) is able to inhibit that response by targeting ERK-1/2 activation. 
The authors suggest that the consumption of green tea may be able to reduce the risk of 
tumour development, since it is tightly dependent on angiogenesis. 
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There are also some examples for Eph-ephrin signaling between endothelial cells and other 
cell types. For proper vascular development, Eph-ephrin signaling also has to take place 
between endothelial cells and the surrounding mesenchymal cells (Adams et al., 2000). 
EphB2 receptors are expressed my mesenchymal cells. Additionally, Eph-ephrin signaling 
plays a role in recruitment of smooth muscle cells towards endothelial cell channels (Car-
meliet et al., 2005). 
Salvucci and her colleagues (2008) have shown that ephrinB2 reverse signaling is crucial 
for assembly of endothelial cells and pericytes. Experiments, in which ephrinB2 expression 
was silenced, resulted in the failure of endothelial cells and bone marrow derived mesen-
chymal stem cells to assemble with each other in cordlike structures.  
 
1.4.4.3 The role of Eph-ephrin signalling in cancer 
 
Ephs and ephrins were also identified to play a crucial part during tumorigenesis (Sur-
waska et al., 2004; Campbell et al., 2008; Mosch et al., 2009; Pasquale, 2010). To enable 
tumor growth, the supply of nutrients, oxygen and growth factors has to be guaranteed. 
Therefore, angiogenesis has to be switched on. Eph receptors and ephrin ligands were 
found to be both up- and downregulated in human carcinomas and in the tumor vasculature 
(Figure 9). As some of many examples, EphA2 and EphB4 are upregulated in malignant 
cancers, whereas EphA1 and EphB6 are downregulated. 
The dysregulation of the ratio between Ephs and ephrins affects a long chain of signaling 
events, leading to severe changes in cell survival, motility, proliferation and organization 
of the cytoskeleton. Activation of EphA2 reduces focal adhesion kinase (FAK) phosopho-
rylation, leading to inhibition of integrin-mediated cell adhesion. Therefore, integrins are 
important players in invasion and metastasis. 
Trying to explain how the disbalance of Ephs end ephrins is established, the binding of 
destabilizing mRNA to Eph/ephrin transcripts and chromosomal alterations was proven in 
tumor cell lines. Furthermore, mutations in the genes encoding all Eph receptors were 
identified. Hypoxia upregulates several Ephs and ephrins, together with other factors like 
tumor necrosis factor-α (TNFα) and VEGF. 
 
Interestingly, Eph receptors expressed in tumor cell lines show a low level of activation by 
ephrins. When triggering forward signaling, proliferation, invasion and metastasis can be 
inhibited by repulsive meachanisms and increased adhesion between tumor cells. There-
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fore, cancer cells try to avoid forward signaling using mechanisms like low expression of 
ephrins, dephosphorylation of the receptor or inefficient interaction of receptor and ligand. 
Reverse signalling seems to have the same capability in some contexts. 
However, both forward and reverse signalling have been shown in many cases to support 
tumour development and angiogenesis. Eph receptors can also be used by other oncogenic 
signalling pathways, making them independent from ephrins. 
 
 
Figure 9. Implications of Eph/ephrin expression in tumorigenesis. Aberrant expression of Ephs 
and/or ephrins results in transformation of normal cells into tumor cells (Surawska et al., 2004). 
  
Elucidating the mechanisms causing the dysbalance in expression of these signaling mole-
cules and their aberrant signalling activities offers the possibility to find putative targets for 
anti-angiogenic cancer therapies. A promising approach is to impair Eph-ephrin signalling, 
which can be achieved in different ways. There have been attempts to use monoclonal an-
tibodies against Eph receptors, which resulted in inhibition of tumor growth. The same 
result has been achieved by blocking signaling with soluble forms of Ephs or ephrins or 
other peptides. It was shown in the literature that soluble EphA2-Fc or EphA3-Fc receptors 
inhibit tumor angiogenesis by competively binding available ligands (Brantley et al., 
2002). 
Other possibilities of intervening are the intracellular use of inhibitors of tyrosine kinases, 
small interfering RNA or antisense oligonucleotides. There have also been attempts to in-
terfere with other pathways regulating cell proliferation and growth. The complexity of 
Eph-ephrin signaling makes it quite difficult, to establish successful targeting strategies 
without side effects, making it necessary to invest further work into this topic. 
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1.4.5 EphA7 as a target gene of SOX18 
  
Previous work in the group has identified EphA7 as a target gene of the transcription factor 
SOX18. HUVEC were transduced with an adenovirus expressing SOX18-IRES-EGFP. 
The mRNA was isolated and used for microarray analysis and real-time PCR.  Follow-up 
experiments have shown that the EphA7 promoter contains several SOX18 binding sites. 
Activation of the EphA7 promoter by SOX18 was verified by reporter gene assays (Hoeth 
et al., unpublished). Therefore, we decided to investigate the functional consequences of 
EphA7 expression in endothelial cells in the context of angiogenesis. 
 
1.5 SOX18 
  
SOX18 is a transcription factor, which is expressed in endothelial cells during embryonic 
development and adult neovascularization. Studies have shown that it is an important regu-
lator of vascular development and a trans-activator of gene expression (Downes et al., 
2001; Hosking et al., 2000). SOX18 belongs to the SOX (Sry-related HMG box) family of 
proteins. Together with SOX7 and SOX17, it forms the SOX Group F. Redundant roles of 
SOX17 and SOX18 were demonstrated previously (Matsui et al., 2006). 
1.5.1 Structure 
 
 
The HMG box of SOX18 recognizes a heptameric DNA consensus sequence 
(WWCAAWG; W= A/T) to which it binds. This binding is believed to recruit other cofac-
tors or transcription factors. The HMG and transactivation domain which were identified in 
SOX18 are conserved between mouse and human. Bioinformatic studies in our lab have 
previously revealed, that three highly conserved blocks are found in the C-terminus of 
SOX18, which were termed proline, charged and serine block due to the occurrence of the 
respective amino acids. Working with mutant constructs of SOX18 showed, that the 
charged block is essential for transcriptional activity. Furthermore, the C-terminus is be-
lieved to mediate interactions with other proteins. 
1.5.2 Expression and roles of SOX18  
 
Studies in mice and chickens have shown that SOX18 is expressed during vasculogenesis 
and angiogenesis. The role of SOX18 in vascular development has been proven by the 
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analysis of ragged mutant mice that carry naturally-occuring mutations in SOX18 and 
which show defects in cardiovascular and hair follicle development (Pennisi et al., 2000).  
 
 
 
Figure 10. Normal form and mutations of SOX18. In case of the Ra, Ra
J
 and Ragl phenotypes, 
mutations are located in the transactivation domain. The Ra
op
 mutation lies outside (Downes et al., 
2001). 
  
The naturally occurring mutant ragged (Ra) and the three allelic mutatations ragged-
Jackson (Ra
J
), ragged-opossum (Ra
op
) and ragged-like (Ragl) result in translational frame-
shifts which leads to the expression of truncated proteins. Therefore, SOX18 dysfunction 
impairs normal vessel development. In constrast to ragged mice, SOX18 knockout mice 
show normal vascular development and are viable. A small reduction in pigmentation is 
the only abnormal phenotype found in these mice. This suggests that other SOX proteins 
may supplant the functions of SOX18. This function is inhibited in the case of ragged 
mice. Mutant forms of SOX18 have been suggested to act in a dominant-negative manner 
by blocking the binding to DNA. 
The expression of SOX18 in the adult mouse was detected by RT-PCR in the lung tissue 
and in the skin after wounding, and at lower levels in heart and skeletal muscle, intestine, 
spleen and kidney. 
Human SOX18 is expressed in various tissues including the heart, brain, skeletal muscle, 
spleen, kidney, liver, small intestine, placenta, lung, colon and thymus (Pennisi et al., 
2000; Saitoh et al., 2002). The hypotrichosis-lymphedema-telangiectasia (HLT) syndrome, 
a hereditary disease characterized by sparse or totally absent hair growth, transparent skin 
on hands and feet and the onset of lymphedema, is caused by a mutation in SOX18 (Irr-
thum et al., 2003). Several SOX genes were found to be involved in human disorders. Be-
cause SOX18 is expressed in Flt-1 (VEGFR-1) knock-out embryos but not in Flk-1 
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(VEGFR-2) null embryos, is has been placed into the VEGF pathway downstream from 
VEGF and Flk-1 (Downes et al., 2001). 
However, signaling pathways of SOX18 still have to be elucidated to get a better insight 
into its functions in vasculogenesis and the maintanance of blood and lymphatic vessels. 
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2 Results 
  
 
Ephs and ephrins are not only neuronal pathfinding molecules as demonstrated in the past 
(Frisén et al., 1997; Sela-Donenfeld et al., 2005; Holmberg et al., 2000), they also control 
vascular development and vessel guidance as they are expressed in endothelial cells (Au-
gustin et al., 2003; Adams et al, 2000; Carmeliet et al., 2005). EphA7, a receptor for ephri-
nA5, was identified as a target gene of SOX18 by microarray analysis and real-time PCR 
in our lab previously. Furthermore, it was shown with bioinformatic tools as well as expe-
rimentally, that the EphA7 promoter contains several SOX18 binding sites.  
These findings and the previous finding, that neuronal cells expressing EphA7 avoided 
cells expressing ephrinA5 (Holmberg et al., 2002), lead to the decision to investigate the 
consequences of expression of EphA7 and ephrinA5 in endothelial cells in context of cell 
migration and proliferation. Furthermore, we wanted to elucidate if Eph-ephrin signaling 
evokes comparable responses in endothelial cells as in neuronal cells. The main aim of the 
project for my diploma thesis was to generate ephrinA-Fc fusion proteins and ephrinA mo-
nomers, to have them ready as tools for further experiments. Furthermore, I was also able 
to collect some preliminary data in in vitro assays of endothelial cell migration. 
 
 
2.1 Generation of ephrinA1-A5 – Fc fusion constructs 
 
 
As it is known from the literature that soluble ephrins do not activate their receptors unless 
they are artificially clustered (Mellitzer et al., 2000), we decided to generate ephrin-Fc fu-
sion constructs. The vector pIGplus, featuring an IgG Fc tail as a functional site, was cho-
sen as cloning vehicle. This leads to expression of ephrin-Fc fusion proteins secreted from 
the cells, which dimerize and are therefore expected to activate the EphA7 receptor. The 
ephrins of the A subfamily, which are GPI anchored membrane molecules, were cloned 
without their GPI anchor. When expressed, they are secreted from the cell and can be har-
vested as soluble proteins suitable for further experiments after purification via their Fc 
part. A fragment of human ephrinA5 encoding 203 amino acids was amplified via PCR 
from an image clone (Gene Service) and then cloned into the vector pIG plus (K. Alitalo) 
(NheI, BamHI). 
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Human ephrinA1 and A3 and murine ephrinA2 and A4 (number of amino acids: see list 
below) were cloned with the same strategy into pIGplus (KpnI, BamHI). 
 
Protein Image Clone Number  Number of amino acids UniProtKB/Swiss-Prot entry 
ephrinA1h AT54-G10 1-182 P20827 
ephrinA2m AV105-D7 1-184 P52801 
ephrinA3h AT20-G1 1-214 P52797 
ephrinA4m D730009E04 1-175 O08542 
ephrinA5h 10097-I05 1-203 P52803 
 
 
 
Figure 11. pIGplus. The gene cloned into the multiple cloning site is expressed as a Fc- fusion 
protein. 
 
 
2.2 Expression of soluble human ephrinA5- Fc fusion protein and Fc 
 
Because we expected a too low yield of protein after transient transfection, we decided to 
generate stable cell lines expressing soluble human ephrinA5-Fc and Fc for control ex-
periments. Cells were cultured in a 10 cm dish until they reached a confluency of about 
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60% and were then transfected with ephrinA5-Fc or the vector Signal pIGplus (Fig. 12) 
using the calcium-phosphate method.  
 
 
 
 
Figure 12. Signal pIGplus. Due to the presence of a CD 33 signal peptide, the Fc tail is expressed 
from this vector. 
 
After selecting for stably transfected cells (10-14 days) with Neomycin (starting concentra-
tion: 800 g/mL), clones were picked and seeded into a 48 well plate. They were further 
cultured in a 10 cm dish. After culturing putative stable clones, the expression of ephri-
nA5-Fc or Fc was verified on Western Blot. Clones with the strongest expression were 
cultivated further and frozen to be kept in liquid N2. 
 
                 
   
Figure 13. Expression of soluble ephrinA5-Fc from eight different stable cell clones (HEK 
293) (antibody: anti- human IgG, Fc specific) 
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Figure 14. Expression of soluble Fc from stable cell clones (HEK 293). The band above origi-
nates from a Fc-dimer (antibody: anti- human IgG, Fc specific). 
 
After verification of the expression, ephrinA5-Fc or Fc were purified from the culture me-
dium using Protein G Sepharose beads to use them for future experiments. Further Western 
Blots, in which the sample was quantified using known amounts of BSA, showed that the 
yield of protein, compared to the used amounts in the literature, was sufficient for cell as-
says even after transient transfection of HEK 293 cells. 
 
 
Figure 15. Expression of soluble Fc (A, B) and ephrinA5-Fc (C, D) from transiently trans-
fected HEK 293 cells (antibody: anti- human IgG, Fc specific). 
 
 
Figure 16. Expression of soluble ephrinA5-Fc from transiently transfected cells (antibody: -
EphrinA5, goat polyclonal IgG). 
 
118 kDa 
  
  90 kDa 
 
  48 kDa 
 
  
  36 kDa 
   
   27 kDa 
  20 kDa   
118 kDa 
  90 kDa 
 
  48 kDa 
   
  36 kDa 
   27 kDa 
  A     B     C     D 
118 kDa 
  90 kDa 
   
  48 kDa 
 
  36 kDa 
  27 kDa 
 
33 
 
 
2.3 Generation of soluble monomeric human ephrinA5 
 
 
To obtain ephrin monomers, which should block Eph receptors, the Xa protease recogni-
tion site between the ephrin and Fc was used. After digestion of ephrinA5-Fc with Xa Pro-
tease, the expression of ephrinA5 was checked on Western Blot. 
 
    
 
 
Figure 17. Expression of soluble ephrinA5-Fc eluted from Protein G Sepharose beads (A, B) 
and expression of soluble monomeric efnA5 (C, D) (antibody: -EphrinA5, goat polyclonal 
IgG). 
 
 
 
2.4 Expression of the constructs human ephrinA1-Fc and ephrinA3-Fc, and 
murine ephrinA2-Fc and ephrinA4-Fc 
 
 
  
A     B 
Figure 18. Transient transfection of HEK 293 with ephrinA1-Fc and E-GFP. (A) phase con-
trast (B) fluorescence. 
 
To verify the expression of the other ephrin-Fc constructs (ephrinA1-A4) by Western Blot, 
HEK 293 cells were transiently transfected using the calcium-phosphate method. The con-
ditioned medium was then used for isolation of the Fc fusion proteins using Protein G Se-
pharose beads.  
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Figure 19. (A-E) Expression of soluble ephrinA1, A2, A3, A4, A5-Fc eluted from with Protein 
G Sepharose beads. EphrinA3-Fc was not expressed. (F-J) Remaining ephrinA1, A2, A3, A3, 
A5-Fc on the beads after elution (antibody: anti- human IgG, Fc specific). 
 
 
As it was demonstrated that the ephrin-Fc fusion proteins and Fc are expressed in stably 
transfected, as well as in transiently transfected cells, in vitro cell assays using the isolated 
proteins could be started. 
 
2.5 Retraction assay I in HUVEC cells 
 
 
The fact that cells expressing EphA7 and cells expressing ephrinA5 avoided each other 
(Holmberg et al., 2002) lead to the first approach, the aim of which was to study the conse-
quences of incubating HUVEC with the construct ephrinA5-Fc.  
Cells cultured in 6 well plates were transiently transfected with the plasmid EGFP-N1 as 
control or IRES-SOX18/GFP in order to stimulate expression of EphA7, using PEI. After 
verification of a successful transfection by checking fluorescence of the cells, 0,3 μg/mL 
Fc as control or ephrinA5-Fc clustered with 0,5 μL/mL antibody (Alexa Fluor goat anti-
human IgG, Molecular Probes) was added to each well. Pictures were taken before and 
after addition of the protein. The microscope table was kept at a temperature of 37°C to be 
as close to incubation conditions as possible. In this experiment, cells transfected with 
EGFP-N1 or IRES-SOX18/GFP did not significantly react to incubation with the control 
construct Fc.  
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HUVEC-GFP 64 min HUVEC-GFP 115 min
HUVEC-GFP 190 min HUVEC-GFP 219 min/ 19min with Fc
A
DC
B
 
 
Figure 20. Fluorescent HUVEC transiently transfected with EGFP-N1 before (A-C) and after 
(D) addition of Fc.  
 
EGFP-N1 transfected cells reacted just as little to ephrinA5-Fc. In contrast, retraction of 
IRES-SOX18/GFP transfected cells after incubation with ephrinA5-Fc could be observed. 
 
25 min prior treatment 10 min with ephrinA5-Fc
24 min with ephrinA5-Fc 55 min with ephrinA5-Fc
A B
C D
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80 min with ephrinA5-Fc 105 min with ephrinA5-Fc
135 min with ephrinA5-Fc 230 min with ephrinA5-Fc
E F
G H
 
 
Figure 21. Fluorescent HUVEC transiently transfected with SOX18-IRES/GFP before (A) 
and after (B-H) addition of ephrinA5-Fc. Red circles mark retracting cells, after 135 min (G) one 
cell even disappeared. 
 
It can be clearly seen that cells retracted significantly during 105 minutes. The cell which 
apparently disappeared and has detached from the dish could be an indicator that the cells 
do not just retract but detach. This is restricted to SOX18 transfected cells and does not 
affect untransfected cells, as Fig. 22 shows. 
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25 min prior treatment 24 min with ephrinA5-Fc
40 min with ephrinA5-Fc 80 min with ephrinA5-Fc
A
DC
B
 
105 min with ephrinA5-Fc 230 min with ephrinA5-Fc
E F
 
It was shown that the effect of retraction is definitively not concerning all cells and that it 
can not be interpreted as general cell death. This supports our hypothesis that EphA7-
ephrinA5 signaling is resulting in a repulsive response in SOX18 transfected cells. Here it 
is necessary to mention that EphA7 is not the only Eph receptor activated by ephrinA5 and 
that other Eph receptors must be involved in evoking that response.  
 
 
 
 
 
Figure 22. The same HUVEC as above transiently transfected with SOX18-IRES before 
(A) and after (B-F) addition of ephrinA5-Fc in phase contrast. (a) Black circles mark the 
transfected cells. (B-F) Red circles mark the same retracting cells as above. 
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2.6 Retraction assay II in HUVEC cells 
 
In my second approach, my aim was to change the previous experiment slightly. In con-
trast to PEI transfection of the cells, they were infected with SOX18/GFP adenovirus. In-
stead of clustering ephrinA5-Fc with an antibody, protein G polystyrene particles (4. 26 
m; Kisker) were used. Infected HUVEC cells were incubated with 5 L/mL protein G 
polystyrene particles and 0,3 g/mL ephrinA5-Fc.  
 
A
DC
B
prior treatment
210 min with ephrinA5-Fc
40 min with ephrinA5-Fc
 
 
Figure 23. HUVEC infected with SOX18/GFP adenovirus before (A and D) and after (B and 
C) incubation with ephrinA5-Fc on protein G polystyrene beads. A-C phase contrast. D fluo-
rescence.  
 
In contrast to the previous experiment, where SOX18/GFP transfected cells completely 
retracted after 105 minutes, no repulsive response could be observed, even at the latest 
time point (210 min). This fact will be discussed later. 
 
2.7 Wound healing assay 
 
 
As angiogenesis is also triggered in wound healing, an in vitro wound healing assay was 
designed to make further studies concerning Eph-ephrin signaling in this context. HUVEC 
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were infected with SOX18/GFP adenovirus and cultivated until they reached confluency. 
A cross was scratched into the layer of cells to observe further migration (Fig. 24).  
 
 
A
 
 
 
B
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Figure 24. HUVEC infected with SOX18/GFP adenovirus. (A, C, E) Immediately after scrat-
ching. (B, D, F) 16 hours after scratching. Addition of Fc (A), ephrinA5-Fc (C) and ephrinA5 mo-
nomer (E). Fc, ephrinA5-Fc and ephrinA5 were added at an amount of 0,3 μg/ mL and were clus-
tered with 0,5 μL/mL antibody. 
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Whereas ephrinA5-Fc should activate and ephrinA5 monomer should block the Eph recep-
tor and make it inaccessible for other ephrin ligands, control Fc fragment should not have 
any effect on ephrin signaling. In all three cases, no prominent differences in scratching 
experiments after 16 hours could be observed.  
Since effects were observed only in one out of three assays, the results remain controver-
sial, and no definitive conclusions can be drawn at this point. In further studies optimiza-
tion of the experimental setup will be required.  
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3 Discussion 
 
 
3.1 Generating ephrin-Fc fusion proteins 
  
 
The emphasis of my project was to generate ephrin-Fc fusion proteins and to verify their 
expression by Western Blot. Since it was shown previously in neuronal cells that the 
ligands for Eph receptors need to be clustered to evoke receptor activity (Mellitzer et al., 
2000; Davis et al., 1994), several groups have used ephrin-Fc fusion proteins in their stud-
ies. 
EphrinA1-Fc fusion proteins have been used by Brantley-Sieders and his colleagues (2003) 
to demonstrate that regulation of endothelial cell migration and vascular assembly caused 
by activation of EphA2 receptor requires activation of Rac1 GTPase by phosphoinositide 
3-kinase. Lawrenson et al. (2001) have shown, that ephrinA5-Fc mediated activation of 
EphA3 in 293T and melanoma cells leads to recruitment of the adaptor protein CrkII to the 
receptor, resulting in activation of RhoA, leading to cytoskeletal changes. 
To proof the repulsive effect of ephrinA5 on migrating cortical interneurons, some of the 
experiments done by Zimmer and her collegues (2008) included the use of ephrinA5-Fc as 
well, like the stripe assay. 
Vidovic et al. (2007) made an interesting discovery using both Eph- and ephrin-Fc fusion 
proteins for experiments with adult bees, in which they showed that Eph-ephrin signalling 
affects learning and memory. 
In another interesting approach, Li and his colleagues (2009) were able to show, that 
treatment of glioma cells with ephrinA5-Fc or EphA2-Fc leads to decreased expression of 
EGFR (epidermal growth factor receptor), proofing with additional experiments that eph-
rinA5 acts as a tumor suppressor in glioma. 
There is a variety of vectors, allowing the expression of Fc-fusion proteins. The gene of 
choice is cloned into the plasmid in frame with the Fc part of an immunoglobulin. This 
strategy allows easy protein purification using protein A or protein G sepharose beads and 
results in the desired clustering of the protein. There is a variety of applications for Fc-
fusion proteins (Flanagan et al., 2007). 
 
The plasmid chosen for my project was pIGplus, into which ephrinA1 to A5 were cloned. 
As illustrated in the Results section, I was able to express the desired soluble Fc-fusion 
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proteins as well as the control Fc protein alone both from stably and transiently transfected 
cells (HEK 293T). After purification using Protein G Sepharose beads, the new tools for in 
vitro assays were ready. Therefore the main aim of my project has been reached by estab-
lishing a new technique and providing the ephrin-Fc fusion proteins to the lab for further 
investigation. 
 
 
3.2 Generating monomeric ephrinA5 protein 
 
 
Since dimerized or clustered ephrins are needed to activate their receptor and evoke a re-
sponse, Ephs blocked by ephrin monomers show a lack of response (Mellitzer et al., 2000; 
Lawrenson et al., 2000). 
For obtaining monomeric ephrin A5, the previously generated Fc- fusion proteins were 
cleaved by the Xa Protease as described previously (Zimmer et al., 2008). Successful ex-
pression of soluble, monomeric ephrin A5 was shown in Western Blot (see the Results 
section) and allowed therefore further usage of the protein. 
 
3.3 In Vitro Assays 
 
 
In addition, I decided to try some preliminary studies using the ephrinA5-Fc fusion pro-
teins. To study the effect of Eph-ephrin signalling on cell proliferation and migration, dif-
ferent approaches were chosen.  
 
3.3.1 Retraction assays 
 
In the first of two different retraction assays (as described in the Results section), retraction 
of SOX18-IRES/GFP transiently transfected HUVEC was observed when they were incu-
bated with ephrinA5-Fc clustered with an antibody (as recommended in the literature- see 
Brantley-Sieders et al., 2003; Zimmer et al., 2008). In control experiments not only non-
transfected cells but also cells transfected with EGFP did not change morphology after 
addition of ephrinA5-Fc.  
 
This result is consistent with data from Lawrenson and his colleagues (2001), who showed 
that w/t 293T cells do not react significantly to treatment with ephrinA5. In comparison, 
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addition of ephrinA5 to cells transfected with the corresponding receptor (EphA3) lead to 
cell rounding and detachment. An effect comparable with my results was shown by Parri et 
al. (2005) in various experiments, in which cells expressing EphA2 retracted when stimu-
lated with ephrinA1-Fc. In this assay I also demonstrated that the control construct Fc did 
not lead to a noticeable response of HUVEC transfected with EGFP or SOX18/GFP.  
Taken together, these findings and the fact that EphA7 is a target gene of SOX18 as it was 
shown in our lab, further support the theory that EphA7- ephrinA5 signalling evokes a re-
pulsive response in cells as already described in literature (Holmberg et al., 2002).  
It is important to mention that also other Ephs of the A subfamily are receptors for eph-
rinA5, not to forget the crosstalk between the A and the B subfamily. Cheng Q. et al (2003) 
reported that ephrinA5 caused morphological changes in PC-3M cells (a prostate epithelial 
cell line) and observed rounding up of the cells. In this article it is not mentioned which 
Eph receptors are expressed by the used cell line, so it is still unclear which Eph receptors 
are involved in the interaction resulting in retraction of the cells caused by ephrinA5. 
In the second retraction assay, HUVEC were not transiently transfected like in the previous 
experiment, but infected with SOX18/GFP adenovirus. Clustering of ephrinA5-Fc was 
achieved by using protein G polystyrene particles instead of an antibody like in the first 
assay. No changes of cell morphology could be observed during incubation of the cells 
with ephrinA5-Fc, which was first hard to believe after the previous approach lead to such 
an interesting result. The used samples and incubation conditions were the same as before. 
One theoretical problem could have been that the polystyrene particles may allow less 
clustering as compared to the use of antibodies. However, this technique has been de-
scribed in the literature (Wimmer-Kleikamp et al., 2004). 
Another important point is that transiently transfecting or infecting the HUVEC with ade-
novirus could also cause a difference in the cell response to the added protein. So it may be 
speculated that the transfection agent or the procedure of transfection might influence the 
biological system. This may have lead to the result that SOX18/GFP transfected cells re-
tracted in contrast to SOX18/GFP adenovirus infected cells during incubation with eph-
rinA5-Fc. 
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3.3.2 Wound healing assay 
 
The wound healing assay, which has been described by Miyoshi et al. (2004) and Parri et 
al. (2005), was chosen as another approach to study cell migration and proliferation. HU-
VEC were infected with SOX18/GFP adenovirus, and then incubated either with eph-
rinA5-Fc, which should activate the Eph receptors, or with ephrinA5 monomer, which 
should block the receptors, or with control Fc, which should have no effect. However, in 
all three cases no changes in cell migration could be observed. In this experiment, again an 
antibody was used for clustering ephrinA5-Fc or Fc as in the first retraction assay. It has to 
be mentioned, that migration of the cells would be easier to observe, if the proliferation 
was stopped, which would be possible by starving them before the experiment in serum-
free medium as it was done by Parri and his colleagues (2005). 
I suppose that in this experiment no significant migration of the cells could be noticed be-
cause proliferation predominated over migration.  
 
3.4 Conclusions 
 
First, it is important to mention that we did not check the ephrinA5-Fc fusion protein, the 
ephrinA5 monomer or Fc for activity in terms of binding to HUVEC, so we do not know if 
these proteins are biologically active. Without this knowledge, the fact that the major part 
of the in vitro assays did not provide the expected data cannot be interpreted. This binding 
of the recombinant proteins to the cells will need to be confirmed by FACS analysis in 
future experiments. 
Furthermore it is known from the literature, that different splice forms of the EphA7 recep-
tor exist, which determine whether repulsion or adhesion/ propulsion is mediated (Holm-
berg et al., 2002). As it is not known which splice form is expressed in case of my experi-
ments, it is very difficult to draw a conclusion. This question should be elucidated by real-
time PCR of HUVEC cells using appropriate primers that cover the respective regions of 
the mRNA. 
Furthermore, incubation conditions during the retraction assays were not optimal. I tried to 
work at a stable temperature, so far this was possible with a microscope table heated to 37 
degrees. For doing reproducible experiments, doing time-lapse microscopy under stable 
conditions for the cells (37 degrees, 5% CO2) would definitely be an advantage. 
47 
 
To try a different approach, ephrinA5 was not just expressed as soluble Fc fusion protein 
without GPI anchor, but also as membrane molecule with GPI anchor. Two cell lines, one 
which constitutively expresses ephrinA5 and another with Ecdysone-inducible expression 
(Invitrogen) of ephrinA5, have been established and co-cultured with HUVEC. It was ob-
served that none of the cells showed any significant reaction.  
All these results show that additional work will be necessary to elucidate the interactions 
between Eph receptors and their ligands, both as soluble constructs and membrane mole-
cules, and their consequences in the context of cell migration and/or proliferation. A more 
systematic approach will be necessary to continue the research on this topic, including first 
steps like verification of binding of the harvested proteins to the cells and confirmation of a 
putative effect of transfection (agent) on cell behavior.  
Furthermore, it is necessary to study the outcome of incubation of HUVEC with the other 
ephrin ligands of the A subfamily, which have already been cloned as Fc fusions, to gain a 
better insight into Eph-ephrin signalling. 
Eph-ephrin signalling has been described in the literature as very complex, including acti-
vation or modification of a variety of other signaling molecules, leading to transduction 
cascades which trigger cellular responses. Different expression patterns of Eph receptors 
and their ligands were shown to even result in a graded outcome of cell repulsion (Mellit-
zer et al., 2000). Also the degree of multimerization of the ephrins activating their receptor 
has an effect on the nature and the strength of the cellular response (Mosch et al., 2009). 
From these and a number of other findings it can be concluded, that a well-considered ap-
proach is necessary to answer some of the many questions appearing in the topic Eph-
ephrin signalling. 
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4 Material and Methods 
 
4.1 DNA techniques 
 
4.1.1.DNA digestion with restriction enzymes 
 
In our lab, all digestions are made with enzymes and buffers from Roche. One unit of re-
striction  enzyme is needed to digest 1 g of DNA in 1 hour at 37°C. There are also excep-
tions concerning temperature (e.g. SmaI). Usually, the DNA is digested in a total volume 
of 15 L. 
 
Standard reaction mix:  x g DNA 
      1,5 L 10x buffer 
      y L enzyme 
      A.d. to 15 L 
4.1.2 Dephosphorylation of linearized plasmid DNA 
 
To prevent religation of the linearized vector, 5 units of Alkaline Phosphatase (Roche) are 
used to remove 5´ phosphate groups of 5 g plasmid DNA in a reaction volume of 50 L. 
The sample is incubated for 1 hour at 37°C. 
 
Standard reaction mix: 5 g plasmid DNA 
    5 L 10x buffer 
    5 L Alkaline Phosphatase 
    A.d. to 50 L   
4.1.3 DNA ligation 
 
After digestion of DNA, fragments with compatible ends can be ligated. The ratio plas-
mid:insert has to be optimised dependent on the size of the fragments. From my expe-
rience, it can vary from 1:1 to 1:3. The sample is incubated for 4 hours at room tempera-
ture or overnight at 16°C.  3-5 L is used for transformation of E.coli.  
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Standard reaction mix: x g plasmid DNA 
    y g insert DNA 
    1 L 10x buffer 
    1 L T4 DNA Ligase (New England Biolabs) 
    A.d. to 10 L 
 
4.1.4 Transformation after ligation 
 
The required amount of competent cells is thawed on ice. 100 L competent cells and at 
least 3 L of the required DNA are mixed on ice and incubated there for 30 minutes. After 
1,5 minutes heat shock (42°C) and 1-2 minutes incubation on ice, 1 mL SOC or LB me-
dium is added. The mix is incubated for 1 hour (200 rpm, 37°C) and pelleted (5 min, 3 
krpm). After decanting 1 mL of the supernatant, the pellet is resuspended in the remaining 
supernatant. The suspension is spread onto a LB- Agar plate containing the appropriate 
antibiotic. After incubation overnight (37°C), colonies can be picked. 
 
4.1.5 Re- Transformation 
  
100 L competent cells and 1 L of the required DNA are mixed and treated just like 
above. 100 L of the mix, which is incubated for 45 minutes (200 rpm, 37°C), is then 
spread onto a LB- Agar plate containing the appropriate antibiotic.  
 
SOC Medium 
 
300 mL LB-Medium 
3 mL 1 M MgSO4 
3 mL 1 M MgCl2 
autoclaved 
180 L 20% Glucose 
sterile filtered 
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4.1.6 Preparation of plasmid DNA from E.coli (Mini-Preps) 
 
Bacterial colonies are picked from LB- Agar plates containing the appropriate antibiotic 
and used to inoculate 5 mL of LB Medium.  After incubation overnight (37°C, 200 rpm), 
the bacterial suspension is pelleted (10 min, 3000 rpm). The supernatant is decanted by 
turning the tubes completely upside down. After resuspending the pellet in 250 L P1 buf-
fer, 250 L P2 buffer is added and the tube is inverted 5-7 times. After 5 min of incubation 
at room temperature, 250 L P3 buffer is added and again, the tube is inverted 5-7 times. 
The tube is centrifuged for 10 min (14 krpm, 4°C) and the supernatant transferred into a 
new tube. After adding 750 L isopropanol to precipitate the plasmid DNA, the tube is 
vortexed and incubated for 20 min at room temperature. Then, the plasmid DNA is pelleted 
(30 min, 14 krpm, 4°C) and the supernatant removed. The pellet containing plasmid DNA 
is washed with 100 L 70% cold ethanol and cetrifuged for 5 min (14 krpm, 4°C). After 
the supernatant is decanted, the pellet is air-dried at room temperature and resuspended in 
50 L TE buffer.  
 
Resuspension buffer P1 (Qiagen) 
 
50 mM Tris-HCl pH 8,0 
10 mM EDTA 
100 g/mL RNase A 
 
Lysis buffer P2 (Qiagen) 
 
200 mM NaOH 
1% SDS (w/v) 
 
Neutralization buffer P3 (Qiagen) 
 
3 M potassium acetate pH 5,5 
 
TE buffer pH 8,0 
 
10 mL 1 M Tris pH 8,0 (Trishydroxymethylaminomethane Ultrapure, USB) 
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2 mL 0,5 M EDTA pH 8,0 
H2O to 1 L 
 
0,5 M EDTA 
 
18,6 g Titriplex III (Ethylendinitrotetraessigsäure Dinatriumsalz Dihydrat, Merck) 
H2O to 70 mL 
10 M NaOH to pH 8,0 
H20 to 100 mL 
 
4.1.7 Preparation of plasmid DNA from E.Coli (Maxi/Midi-Prep)- QIAGEN 
 
Bacterial colonies are picked from LB- Agar plates containing the appropriate antibiotic 
and used to inoculate 250/100 mL of LB Medium. After incubation overnight (37°C, 200 
rpm), the bacterial suspension is pelleted (15 Min, 4000 rpm). The pellet is resuspended in 
10/4 mL buffer P1 and incubated for 5 minutes at room temperature. After addition of 10/4 
mL buffer P2, the tube is inverted 6 times and the lysate incubated for 5 minutes at room 
temperature. Then, 10/4 mL buffer P3 is added, the tube is inverted 6 times and incubated 
for 20 minutes on ice. After centrifugation (5 min, 4 krpm), the sample is filtrated through 
a Whatman filter. In case the sample is further used for transfections of cells, endotoxin 
removal buffer is added (1/10 of the volume of the filtrate) and the sample incubated for 30 
minutes on ice. A Qiagen-tip 500/100 is equilibrated with 10/4 mL buffer QBT and the 
sample applied. After washing the tip with 2x 30/10 mL buffer QC, the DNA is eluted with 
15/5 mL buffer QF into a Corex tube. The DNA is precipitated with 10,5/3,5 mL (0,7 vo-
lumes) isopropanol. The tube is mixed and centrifuged (30 min, 9 krpm, 4°C). After de-
canting the supernatant, the DNA pellet is washed with 5/2 mL 70% ethanol and centri-
fuged (5 min, 13 krpm, 4°C). Then, the ethanol is taken off, the DNA allowed to air- dry 
and resuspended in 100/50 L 1x TE buffer (pH 8,0) or TE endotoxinfree buffer. Even-
tually, the DNA sample can be precipitated once more after the isopropanol step with so-
dium-acetate and ethanol abs.. (see: precipitation of DNA) 
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4.1.8 Preparation of plasmid DNA from E.Coli (Maxi-Prep)- INVITROGEN 
 
Usage Instead of buffer..  
Resuspension P1 R3 
Lysis P2 L7 
Neutralization P3 N3 
Equilibration QBT EQ1 
Washing QC W8 
Elution QF E4 
 
The column is equlibrated with 30 mL EQ1. After addition of N3 to the sample, it is centri-
fuged (10 min, 5000 rpm) and then filtrated. When the sample is applied to the column, it 
is washed with 60 mL W8. The other steps are exactly the same as above. 
 
4.1.9 Precipitation of DNA 
 
1/10 of volume 3 M sodium-acetate (pH 2,5) and 2,5 volumes ice-cold ethanol abs. are 
added and the sample centrifuged (30 min, 13 krpm, 4°C). After washing it with 70% 
ethanol, it is centrifuged (5 min, 13 krpm, 4°C). The ethanol is removed and the pellet al-
lowed to air-dry. The DNA is resuspended in a suitable volume of 1x TE buffer (pH 8,0) or 
TE endotoxinfree buffer. 
 
4.1.10 Isolation of genomic DNA from HEK293 cells 
 
HEK293 cells are cultivated in a 10 cm dish until they reached confluency. After addition 
of 3 mL lysisbuffer and 150 L Proteinase K (final conc. 0,5 mg/mL; Sigma), the lysate is 
incubated for 4 hours at 55°C and then transfered into 4 eppendorf tubes. They are mixed 
for 5 minutes (14 krpm) and then, 250 L 6M NaCl is added to each tube. After shaking 
the tubes for 5 minutes by hand, they are centrifuged (7,5 min; 13,2 krpm). 750 L of su-
pernatant is transfered to a fresh tube  and mixed with 500 L isopropanol. DNA now be-
comes visible and the samples are incubated for 5 minutes at room temperature. After cen-
trifugation (2 min, 2000 rpm), supernatants are taken off and the pellets washed with 70% 
ethanol. Each pellet is resuspended in 50 L 1x TE (pH 8,0) and the samples are pooled. 
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Lysisbuffer 
 
10 mL 0,5 M Tris-HCl pH 8,0  
20 mL 0,5 M EDTA pH 8,0   
10 mL 1 M NaCl    
5 mL 20% SDS (Sodium Dodecyl Sulfate Ultra Pure, MP Biomedicals) 
H2O to 100 mL 
 
4.1.11 Determination of DNA concentration 
 
100 L A. dest. is used as blank. 1 L of the DNA sample is mixed with 99 L A. dest and 
its absorption measured at 260 nm / 280 nm with a spectrophotometer (Pharmacia Bio-
tech). The DNA concentration is calculated with the following formula:  
 
OD260 nm x 50 (specific factor for dsDNA) x 100 (dilution factor)  / 1000 = 
 
= DNA concentration g/ L  
The ratio is an index for the purity of the DNA sample with an optimum between the val-
ues 1,8 and 2. 
 
4.1.12 Agarose gel 
 
DNA fragments are separated according to their size on an agarose gel. Usually (dependent 
on the expected fragment lenght), a 1% gel is made. For that, 1g agarose (Agarose MP, 
Roche) is melted in 100 mL 1x TAE buffer. After addition of 5 L ethidium bromide (In-
vitrogen; final conc. 0,5 g/mL), the gel is poured and the comb inserted. 
Aliquots of the samples are mixed with DNA gel-loading buffer and loaded onto the gel. 7 
L marker (GeneRuler 1kb DNA Ladder, Fermentas) is used for determination of fragment 
size. DNA is visualized under UV light. 
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50x TAE buffer 
 
242 g Tris base    
57,1 mL Glacial acetic acid 
100 mL 0,5 M EDTA pH 8.0  
H2O to 800 mL 
HCl to pH 8,5 
H2O to 1 L 
 
4.1.13 Purification of DNA from agarose gels (GFX PCR DNA & Gel Purification Kit, 
Amersham) 
 
The slice of agarose containing the DNA of interest is cut out with a razorblade and 
weighed in a tube. After adding capture buffer (10 L for 10 mg), the sample is incubated 
at 60°C until melting of the agarose (about 5 min). When the sample is applied onto the 
column, it is incubated for one minute at room temperature. Then it is centrifuged (30 s, 14 
krpm) and the collection tube emptied. After adding 500 L washing buffer, the sample is 
centrifuged as above. The column is placed into a fresh tube and 30 L 1x TE (pH 8,0) are 
added. After incubation for one minute at room temperature, the sample is centrifuged. (1 
min, 14 krpm). 
 
4.1.14 Sequencing DNA samples 
 
Samples from our lab are sent to MWG Biotech (www.mwg-biotech.com).  
5 g DNA is precipitated and centrifuged (30 min, 13 krpm, 4°C). The supernatant is re-
moved and the pellet allowed to air-dry.  
If special primers are needed, 5 L primer 100 ng/ L  is sent with the sample. 
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4.2. Cell culture 
 
4.2.1 Used cell lines 
 
HEK (human embyonic kidney) 293T cells are purchased from ATCC.  
HUVEC (human umbilical venous endothelial cells) cells are isolated from umbilical cords 
(Warren, J.B., 1990, The endothelium, Wiley-Liss New York, p. 263) in our lab. 
 
4.2.2 Culture conditions 
 
All cells are cultured at 37°C and treated under sterile conditions. All dishes (except flasks 
for HEK) are coated with 1% gelatine/PBS. 
HEK 293 cells are grown in DMEM complete and HUVEC cells in M199 complete. 
4.2.3 Media 
 
DMEM complete (for HEK 293) 
 
500 mL DMEM (HyQ DMEM/High Glucose Dulbecco´s Modified Eagles Medium, HyC-
lone) 
10% FCS (Gibco) 
5 mL Glutamine (200 mM) 
5 mL Penicillin/Streptomycin (Bio Whittaker, 10 mg/mL) 
sterile filtered 0,2 m 
 
M199 complete (for HUVEC cells) 
 
500 mL M199 (BioWhittaker) 
10 mL PSFG (Bio Whittaker) 
20% FBS (PAN Biotech) 
30 g/mL ECGS (Techno Clon) 
5U/mL Heparin (Roche) 
sterile filtered 0,2 m 
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Serum-free medium (for HEK 293) 
 
100 mL medium (Ex-Cell 293, SAFC Biosciences) 
3 mL Glutamine (200 mM) 
3 mL Penicillin/Streptomycin (10 mg/mL) 
 
 
4.2.4 Passaging cells 
 
After removing the medium, cells are washed with PBS (BioWhittaker) and Trypsin 
(Trypsin EDTA, BioWhittaker) is added. When the cells round up, the Trypsin is stopped 
by adding complete medium. Therefore, the cells are resuspended in the required volume 
of medium and seeded into a new dish. 
 
4.2.5 Freezing and thawing cells 
 
For freezing cells, they are washed twice with PBS, trypsinized and resuspended in com-
plete medium. After centrifugation (5 min, 1000 rpm), the supernatant is taken off and the 
cell pellet resuspended in medium M199 or DMEM + same volume serum, 10% DMSO 
(Dimethyl Sulphoxide Hybri-Max, Sigma) . Pre-cooled cryogenic vials (Nalgene) are 
filled with 1 mL of cell suspension, put into a cellfreezer (Cell Freeze Container, Nalgene) 
and then placed at –80°C overnight to achieve cooling –1°C/min. Then, the vials are stored 
in a liquid nitrogen container. 
For thawing cells, the cryogenic vials are placed into a waterbath (37°C). As soon as there 
is hardly any ice left, cells are immediately transferred into prewarmed medium and further 
cultivated. 
 
4.2.6 Calcium- phosphate transfection of HEK 293 cells (transient) 
 
Cells are cultured in a 6 well plate (2 mL medium/ well) until they are 60-70% confluent. 
In a 4 mL polypropylene tube, 59 L A. dest. is mixed with 4 g DNA. After addition of 9 
L 2 M CaCl2, 72 L 2x HeBS (Hepes buffered saline) is added drop-wise. The tube is 
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shaken and after 3-4 minutes of incubation, the mixture is added drop-wise to one well. 
After 24 hours, medium is exchanged. After 48 hours, cells are harvested. 
 
2 M CaCl2  
CaCl2 x 2 H2O (Merck) 
sterile filtered through 0,2 m filter 
 
2x HeBS     
400 mL H2O 
8 g NaCl  
0,107 g Na2HPO4 (Merck)  
6,5 g Hepes (Sigma)  
H2O to 800 mL  
HCl to pH 7,05 
H2O to 1 L 
sterile filtered through 0,2 m filter 
 
4.2.7 Reporter gene assay 
 
Cells are cultured in a 12 well plate and transiently transfected in triplicates. After 48 
hours, they are lysed with 50 L lysisbuffer (Passive Lysis Buffer 5x, Promega) and sha-
ken for 30 minutes at room temperature. The lysate is then used for measuring luciferase 
activity. 5 L is mixed with 350 L reaction mix containing ATP and the sample is meas-
ured in a luminometer (Lumat LB 9501, Berthold). For each sample, 100 L injection mix 
containing luciferin is injected.  
For measuring - galactosidase expression, a 96 well plate is used for mixing 5 L lysate 
with 95 L CPRG. After a change of color is noticed (time varies for different amounts of 
- gal), absorbance is measured at 570 nm in an ELISA plate reader (SLT 340 ATTC). 
All data are expressed as RLU (relative light units)/ -gal. Additionally, the fold induction 
is calculated, which shows expression levels in comparison to mock- expression levels.  
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Injection Mix 
 
9 mL 25 mM Glycylglycine pH 7,8 (Sigma)  
1 mL 20 mM ATP pH 7,4 (Sigma)    
0,1 mL 1 M MgSO4   
 
Reaction Mix 
 
4 mL 25 mM Glycylglycine pH 7,8 
1 mL 1 mM Luciferin (BioThema)  
Luciferin is only soluble in A. dest., when NaOH is added. 
 
CPRG (Roche) 
 
0,5 mg/mL in 1x PBS def. + 0,1% BSA (Sigma) 
 
4.2.8 PEI transfection of HUVEC cells 
 
Cells are cultured in 6 well plates until they are 40-80% confluent. In a 4 mL polypropy-
lene tube, 2 g DNA is mixed with 125 L HBS. After mixing in a second tube 2-10 L 
PEI and 125 L HBS, the PEI solution is added drop-wise to the DNA solution. The mix is 
incubated for 20 minutes at room temperature. 
After washing the cells with PBS, 800 L Optimem (OptiMEM I, Gibco) is added to each 
well. The PEI-DNA solution is added drop-wise to the medium and after 2-4 hours, 2 mL 
M199 complete is added to each well. After 24 hours, cells are harvested. 
 
2x HBS: see 2x HeBS 
HCl to pH 7,4 
 
PEI (Sigma-Aldrich) 
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4.3 Bacterial techniques and media 
 
4.3.1 Generating chemical competent cells 
 
2 mL of a bacterial preculture is inoculated to 200 mL LB medium. Cells are incubated at 
37°C (200 rpm) until the OD of 0,4 (595 nm) is reached. After centrifugation (15 min, 4 
krpm, 4°C), the pellet is resuspended in 20 mL ice-cold TSS buffer on ice and 5 mL 87% 
glycerol is added. Aliquots of 250 L are made and frozen in liquid N2. Storage –80°C. 
 
TSS buffer 
 
10 g PEG 
1 mL 1 M MgCl2 
1 mL 1 M MgSO4 
93 mL  LB-Medium 
5 mL DMSO 
sterile filtered 
 
4.3.2 Preparing glycerol- stocks 
 
1 mL of the bacterial overnight- culture is mixed with 1 mL 30% glycerol and then put on 
–80°C. 
 
4.3.3 Media 
 
LB Medium 
 
20g/L LB Broth Base (Invitrogen) 
 
LB Agar plates 
 
15g agar (Bacto Agar, Difco)/ L LB medium 
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Used antibiotics for bacteria 
 
Antibiotic 
(Sigma) 
Stock concen-
tration 
Working 
concentration 
Ampicillin 50 mg/mL 100 g/mL 
Kanamycin 10 mg/mL 50 g/mL 
 
 
 
4.4 Special protein techniques  
 
4.4.1 Isolation of ephrin-Fc fusion proteins/ Fc fragments with Protein G Sepharose beads 
 
HEK 293 cells are cultured for two days after transfection in serum-free medium. Condi-
tioned medium from the cells secreting the ephrin-Fc fusion protein or the Fc- fragment is 
collected and centrifuged in a Falcon tube (5 min; 4,5 krpm). After incubating the superna-
tant with Protein G Sepharose beads (Protein G Sepharose 4 Fast Flow, GE Healthcare; for 
40-50 mL medium 50 L beads) for 15 minutes at 4°C, it is centrifuged (2,5 min; 500 
rpm). The supernatant is taken off and the beads are washed twice with diluted 1x PBS 
(1:3) at a centrifugation speed of 1 krpm for 1 minute. After taking off the supernatant, 200 
L elution buffer (0,1 M glycine pH 2,5) is added to the beads. The tubes are mixed by 
inverting them for 10 minutes at 4°C and then centrifuged (1 min, 14 krpm). The superna-
tant is transfered into a new tube containing 23 L neutralisation buffer (0,4 M Tris-HCl 
pH 8,8). 150 L 1 M Tris-HCl pH 8,0 and 400 L 87% glycerol are added and the sample 
is stored at –20°C. 
 
4.4.2 Digestion of ephrin-Fc fusion proteins with Xa protease 
 
When the sepharose beads from the previous steps are washed with diluted 1x PBS for the 
first time, about one third of the prep is used to incubate the beads with Xa Protease reac-
tion buffer. After taking off the supernatant, 100 L reaction buffer is added to the beads. 
The sample is incubated with 3 L Xa Protease (Factor Xa Protease 400 units, Qiagen) and 
1 L Heparin overnight at 37°C. Then, the sample is centrifuged to collect the remaining 
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beads at the bottom of the tube and the supernatant is mixed in a new tube with 75 L 1M 
Tris-HCl pH 8,0 and 200 L 87% Glycerin. The sample is stored at –20°C. 
 
Xa Protease Reaction buffer 
 
4 mL 500 mM Tris-HCl pH 6,8   
1 mL 5 M NaCl     
0,1 mL 1 M CaCl2     
 
4.4.3 Removal of Xa protease after digestion 
 
150 L Xa Removal Resin (Qiagen) is centrifuged (5 min, 1 krpm). After taking off the 
supernatant, 750 L reaction buffer is added to the beads and centrifuged. The supernatant 
is taken off and the sample from the previous step (after incubation overnight) is added. It 
is incubated for 10 minutes at 4°C and then centrifuged (5 min, 1 krpm). The supernatant is 
stored. 
 
 
4.5 Verification of gene expression 
 
 
4.5.1 SDS- Page (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) 
 
This technique is used to separate proteins according to their size.  
After pouring the separation gel (the chosen percentage is dependent on the molecular 
weight of the protein), it is overlaid with butanol and allowed to polymerize. Then, the gel 
is washed with distilled water, the stacking gel poured and the comb inserted. After poly-
merization, the whole gel is inserted into the chamber of the apparatus containing running 
buffer. After mixing the samples with gel-loading buffer and heating them for 10 minutes 
on 95°C, aliquots are loaded onto the gel. On a single lane, 7 L of  Prestained Protein 
Molecular Weight Marker (Fermentas; 0,2 mg/mL of each protein) is loaded. Electropho-
resis is done at a voltage of 70V. 
To visualize all proteins after SDS-Page, a Coomassie staining can be done. A Western 
Blot is necessary to detect your specific protein of interest and for determining its size. 
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Gel percentage protein size range 
10%   21 – 100 kDa 
12%   10 – 40 kDa 
 
Separation gel 10% 12,5% 
 A. dest. 4,1 mL 3,3 mL 
Solution A 2,5 mL 2,5 mL 
Solution B 3,4 mL 4,2 mL 
10% APS 50 L 50 L 
TEMED 10 L 10 L 
 
 
Solution A 
 
181,5 g Tris  
4 g SDS  
HCl to pH 8,8  
A.d. to 1 L 
 
Solution B 
 
75 mL 40% Acryl- Bis-acrylamide (29-1 Mixture 40% Solution, Qbiogene) 
25 mL A.d. 
 
Solution Ast 
 
60 g Tris 
4 g SDS 
400 mg Phenolred 
HCl to pH 6,8 
A.d. to 1 L 
 
10% APS 
 
N, N, N´, N´- Ammonium Persulfate, International Biotechnologies 
Stacking gel  
A. dest. 3,1 mL 
Solution Ast 1,25 mL 
Solution B 0,65 mL 
10% APS 50 L 
TEMED 10 L 
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TEMED 
 
Tetramethylethylenediamine, Fluka 
 
10x Running buffer 
 
30 g Tris 
144 g Glycine (Fluka) 
10 g SDS 
A.d. to 1 L 
 
2x SDS gel-loading buffer 
 
150 mM Tris-HCl pH 6,8 
300 mM DTT 
6% SDS 
0,3% Bromphenolblue (Fluka) 
30% Glycerol 
 
4.5.2 Western Blot 
  
The components for the „blot sandwich“ are soaked with blotting buffer and then put into 
the blotting apparatus as follows: black- sponge- 2 whattman papers (9 x 7 cm)- gel- mem-
brane (size according to gel. Hybond-C Extra, Amersham)- 2 whattman papers- sponge- 
white. Blotting is carried out for 1,5 hours at 300 mA. Afterwards, the membrane is 
washed with PBS Tween to remove the methanol and incubated for a few minutes in Pon-
ceau S solution. After washing it three times with water, the protein bands become visible. 
Then, the membrane is blocked with 5% skim milk (Merck) in PBS Tween + 0,02% NaN3 
for 30 minutes to avoid unspecific binding of the antibodies and washed 3 times with PBS 
Tween. The membrane is incubated overnight at 4°C with the primary antibody (in PBS 
Tween + 1% BSA + 0,02% NaN3). Next day, the membrane is washed 3 times with PBS 
Tween and incubated with the secondary antibody (in PBS Tween) for one hour at room 
temperature. This antibody binds to the primary antibody and is coupled to the enzyme 
horse raddish peroxidase (HRP). After washin with PBS Tween 3 to 4 times (each at least 
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5 minutes), the membrane is incubated for 5 minutes with the substrate (SuperSignal West 
Pico Chemiluminiscent Substrate, Pierce). The light generated in this reaction is captured 
on an X-ray film (Fujifilm Super RX) giving a black band representing the protein of inter-
est, whose size is determined according to the marker. 
In case a directly conjugated antibody is used, membranes are blocked, washed and then 
incubated with the antibody for one hour at room temperature.  
 
Blotting buffer 
 
100 mL 10x running buffer 
200 mL methanol 
700 mL A.d. 
 
10x PBS (phosphate-buffered saline) 
 
80 g NaCl    
2 g KCl    
17,8 g Na2HPO4 x 2 H2O  
2,4 g KH2PO4   
H2O to 800 mL 
HCl to pH 7,4 
H2O to 1 L 
 
PBS Tween 0,1% 
 
1 mL Tween (Plus One Tween 20, Amersham Biosciences)  
1 L PBS 
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4.6 Used antibodies 
 
Antibody Company Dilution 
Anti- human IgG, Fc specific (Peroxidase Conjugate) Sigma 1:2000 
EphrinA5, goat polyclonal IgG Santa Cruz 1:200 
Donkey anti-goat IgG- HRP Santa Cruz 1:5000 
 
In case the ephrin A5 antibody is used, additional blocking (1 hour) after the last washing 
step is necessary. 
 
4.7 Primers for cloning 
 
Name Sequence Restriction 
sites 
ephrinA1h 
forward 
ATGGGGTACCACCATGGAGTTCCTCTGGGCC KpnI 
ephrinA1h 
reverse 
AACGGGATCCATACTGTGAGCGATGCTATGTAG BamHI 
ephrinA2m 
forward 
ATGGGGTACCACCATGGCGCCCGCGCAGCGC KpnI 
ephrinA2m 
reverse 
AACGGGATCCATGTTACTGGTGAAGATGGGCTC BamHI 
ephrinA3h 
forward 
ATGGGGTACCACCATGGCGGCGGCTCCGCTG KpnI 
ephrinA3h 
reverse 
AACGGGATCCATCCCGCTGATGCTCTTCTCAAG BamHI 
ephrinA4m 
forward 
ATGGGGTACCACCATGCGGCTGCTGCCCCTG KpnI 
ephrinA4m 
reverse 
AACGGGATCCATGCTTTCTCCAGGACTCCCAAC BamHI 
ephrinA5h 
forward 
AACTAGCTAGCATGTTGCACGTGGAGATG NheI 
ephrinA5h 
reverse 
AAGCGGGATCCAAGTTCTCGCCGCGGGAT BamHI 
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